Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021

Rhea-AI Summary

Insmed Incorporated (Nasdaq:INSM) will release its third quarter 2021 financial results on October 28, 2021. A conference call will follow at 8:30 a.m. ET to discuss the results and offer a business update. Participants can join via phone or through a live webcast on the company's website. Insmed focuses on rare and serious diseases, with its first product being a therapy approved in multiple regions, including the US, Europe, and Japan. The company is also developing investigational therapies in high-need areas.

Positive

• First commercial product approved in the US, Europe, and Japan.
• Developing investigational therapies targeting serious unmet needs.

Negative

• None.

BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2021 financial results on Thursday, October 28, 2021.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, October 28, 2021 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S. toll free), (646) 904-5544 (U.S. local), or +44-208-0682-558 (international) and referencing access code 594997. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 1 hour after its completion through November 26, 2021 by dialing (866) 813-9403 (U.S. toll free), (929) 458-6194 (U.S. local), or +44-204-525-0658 (international) and referencing access code 963633. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-third-quarter-2021-financial-results-conference-call-on-thursday-october-28-2021-301399678.html

SOURCE Insmed Incorporated

FAQ

When will Insmed announce its Q3 2021 financial results?

Insmed will announce its third quarter 2021 financial results on October 28, 2021.

What time is Insmed's conference call for Q3 2021 results?

The conference call will take place at 8:30 a.m. ET on October 28, 2021.

How can I participate in Insmed's Q3 financial results call?

Participants can join by dialing specific phone numbers or through a live webcast on Insmed's website.

What is Insmed focused on in its business?

Insmed is focused on transforming the lives of patients with serious and rare diseases.